



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Mitiglinide calcium hydrate (Standard)

| | |
|---------------------------|---|
| Cat. No.: | HY-B0682AR |
| CAS No.: | 207844-01-7 |
| Molecular Formula: | C ₁₉ H ₂₄ NO ₃ ·1/2Ca·H ₂ O |
| Molecular Weight: | 352.46 |
| Target: | Potassium Channel |
| Pathway: | Membrane Transporter/Ion Channel |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | Mitiglinide (calcium hydrate) (Standard) is the analytical standard of Mitiglinide (calcium hydrate). This product is intended for research and analytical applications. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K ⁺ (K _{ATP}) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell K _{ATP} channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes ^{[1][2]} . |
| IC₅₀ & Target | K _{ATP} channel ^[1] |

REFERENCES

- [1]. Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K⁺ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. *Eur J Pharmacol.* 2001 Nov 9;431(1):119-25.
- [2]. Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. *Clin Exp Pharmacol Physiol.* May-Jun 2002;29(5-6):423-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA